ERBB2 and breast cancer: Our data revealed improved growth inhibition of colonies in the case of combination treatment compared to single agent cases (3), The Gompertz model is validated as a suitable model to describe the growth pattern of breast cancer cell lines, and (4) the combination treatment with TZ and BMS-202 decreased the cell’s invasiveness along with altering several key pathways, such as AKT/mTOR and ErbB2 compared to monotherapy.